Shares of Tesaro Inc. (NASDAQ:TSRO) were up 3.7% during mid-day trading on Thursday . The company traded as high as $94.19 and last traded at $93.51, with a volume of 379,522 shares. The stock had previously closed at $90.18.

A number of analysts recently issued reports on TSRO shares. FBR & Co started coverage on Tesaro in a research note on Wednesday, April 13th. They set an “outperform” rating and a $65.00 target price for the company. Zacks Investment Research raised Tesaro from a “hold” rating to a “buy” rating and set a $47.00 target price for the company in a research note on Thursday, April 28th. Jefferies Group reissued a “buy” rating on shares of Tesaro in a research note on Sunday, May 8th. Credit Suisse Group AG began coverage on Tesaro in a research note on Friday, May 13th. They set an “outperform” rating and a $56.00 target price for the company. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Tesaro in a research note on Thursday, May 19th. Two investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $79.42.

The stock’s 50 day moving average is $82.97 and its 200 day moving average is $52.36. The firm’s market capitalization is $4.80 billion.

Tesaro (NASDAQ:TSRO) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.71) by $0.43. The business earned $36.60 million during the quarter, compared to analyst estimates of $4.98 million. During the same period in the previous year, the company earned ($1.51) EPS. On average, analysts expect that Tesaro Inc. will post ($7.29) earnings per share for the current fiscal year.

In related news, VP Jeffrey H. Hanke sold 12,500 shares of the firm’s stock in a transaction on Thursday, June 30th. The shares were sold at an average price of $74.35, for a total transaction of $929,375.00. Following the completion of the sale, the vice president now directly owns 12,500 shares of the company’s stock, valued at approximately $929,375. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Edward C. English sold 7,000 shares of the firm’s stock in a transaction on Friday, June 10th. The shares were sold at an average price of $40.75, for a total transaction of $285,250.00. Following the sale, the vice president now directly owns 3,500 shares of the company’s stock, valued at $142,625. The disclosure for this sale can be found here.

Other large investors have recently added to or reduced their stakes in the company. Jennison Associates LLC raised its stake in Tesaro by 157.5% in the fourth quarter. Jennison Associates LLC now owns 938,461 shares of the biopharmaceutical company’s stock worth $49,100,000 after buying an additional 574,041 shares during the last quarter. Bank of Montreal Can raised its stake in Tesaro by 9,925.5% in the fourth quarter. Bank of Montreal Can now owns 24,362 shares of the biopharmaceutical company’s stock worth $1,275,000 after buying an additional 24,119 shares during the last quarter. Mutual of America Capital Management LLC raised its stake in Tesaro by 95.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 39,520 shares of the biopharmaceutical company’s stock worth $2,068,000 after buying an additional 19,320 shares during the last quarter. Rhumbline Advisers raised its stake in Tesaro by 9.3% in the fourth quarter. Rhumbline Advisers now owns 22,403 shares of the biopharmaceutical company’s stock worth $1,172,000 after buying an additional 1,915 shares during the last quarter. Finally, Nationwide Fund Advisors raised its stake in Tesaro by 1.3% in the fourth quarter. Nationwide Fund Advisors now owns 26,647 shares of the biopharmaceutical company’s stock worth $1,394,000 after buying an additional 330 shares during the last quarter.

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.